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United Kingdom.KEY TEACHING POINTS
 Catheter ablation in the presence of a Tendyne
mitral valve prosthesis (Abbott, Santa Clara, CA) is
feasible.
 Exclusive retrograde aortic access is strongly
advised.
 Limited access to the basal–mid anterolateral left
ventricle should be anticipated.Introduction
Catheter ablation is widely used for the control of ventricular
tachycardia (VT) in structural heart disease. Patients in this
group can be highly complex, with multiple comorbidities,
and have often had prior cardiac surgery. Increasing numbers
of these patients are now being treated with percutaneous op-
tions for valve replacement/repair. As such, we are seeing pa-
tients referred with these devices to our arrhythmia services
who require catheter ablation. We present the first reported
case of VT ablation in the presence of the Tendyne mitral
valve prosthesis (Abbott, Santa Clara, CA). Fluoroscopy and intracardiac echocardiography
should be used to simultaneously view the valve
struts and the valve tether intraprocedurally.Case report
A 77-year-old man with ischemic cardiomyopathy under-
went VT ablation with the Tendyne mitral valve device in
situ. The patient had a past history of coronary artery bypass
grafting in 2001, followed by an inferior myocardial infarc-
tion in 2013, after which a primary prevention cardiac re-
synchronization therapy defibrillator was implanted. A
successful endocardial VT ablation was undertaken in 2014
following recurrent monomorphic VT requiring shock ther-
apy, and he remained free of VT for a total of 5 years. How-
ever, worsening heart failure ensued owing to severe mitral
regurgitation and, after surgical turn-down, he was referred
for the Tendyne mitral valve implant in 2018. Recurrence
of VT requiring frequent shocks occurred in late 2019, after
which he was placed on amiodarone. The patient then suf-
fered VT storm in early 2020 requiring control with mexile-
tene but with breakthrough owing to slow VT, and therefore
VT ablation was planned.KEYWORDS Ventricular tachycardia; Ablation; Percutaneous mitral valve;
Tendyne valve; Intracardiac echocardiography
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the Tendyne device. Figure 2 shows intraprocedural data dur-
ing VT mapping and ablation.
Ablation was undertaken with general anesthesia. Three-
dimensional electroanatomical mapping was undertaken
with intracardiac echocardiographic (ICE) guidance under
full heparinization. Owing to the presence of a dense network
of valve struts, we considered the transmitral route contraindi-
cated, so left ventricular access was exclusively via the retro-
grade aortic route. Mapping was performed via a single
bidirectional ablation catheter, as we were concerned that
multi-spline mapping catheters may become entangled.
Voltagemapping identified a discrete inferolateral scar. How-
ever, it was apparent that access to the basal to mid anterior
and anterolateral segments was severely restricted through
the aortic route, mainly owing to the presence of the valve
struts, the total diameter of which appeared to occupy a signif-
icant proportion of the periannular area and extending further
apically past the annular plane. The tether could be negotiated
readily under ICE guidance. Mapping was carefully under-
taken with fluoroscopy, which enabled visualization of the in-
dividual valve struts but not the tether, and ICE, which was
able to visualize the tether but not the detail of the struts. Aen access article
.0/).
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Figure 1 The top row of images show the Tendyne device (Abbott, Santa Clara, CA) during transesophageal echocardiography (TEE) at 0, 60, and 120
probe angulation. The bottom left panel shows a long-axis intracardiac echocardiographic (ICE) image of the device, valve struts, and tethering anchor. The bot-
tom right panel shows an ex vivo image of the Tendyne device.
Figure 2 A: Ventricular tachycardia (VT) termination during ablation with mid-diastolic potential (red arrow) (gained up distal bipole). B, C: The intrapro-
cedural appearance of the device from orthogonal fluoroscopic views with the ablation catheter at the site of VT termination.D, E:A steep left anterior oblique and
posteroanterior view, respectively, of the electroanatomical substrate map with voltage settings 0.5–1.5 mV acquired during the ablation procedure; ablation
lesion set shown with termination point (white arrow).
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stimulation and activation mapped to the mid lateral border
of the inferior scar, where entrainment with concealed fusion
was obtained, and ablation led to clean termination. There-
after, the patient remained noninducible, and further substrate
modification was undertaken to the remainder of the scar to
achieve abolition of late activity. Postprocedure imaging
showed no change in mitral valve function. Mexiletene was
stopped immediately post ablation and amiodarone was with-
drawn at the 3-month clinic follow-up. There was no VT
recurrence at 5 months follow-up.
Discussion
TheTendyne device is a porcine trileaflet pericardial valve su-
tured to a self-expanding nitinol frame and is anchored with a
polyethylene tether through the left ventricular apex and
secured epicardially. Implantation occurs off-pump via a
left minithoracotomy through a transapical approach and de-
ployed through a 34F sheath, and the tension on the tether is
adjusted according to optimal positioning. First-in-human im-
plantation was reported in 2016 and the results of a global CE
mark study from the first 100 patients have been published.1,2
This case demonstrates the challenges and need for simul-
taneous multimodality imaging for procedural guidance inthese complex patients. In our opinion, VT ablation should
only be done via a retrograde aortic route and extreme diffi-
culty in accessing the mid to basal anterior/anterolateral wall
should be anticipated. However, the tether did not represent a
major barrier to navigating with the ablation catheter. Owing
to the limited access to the basal anterior/anterolateral left
ventricular segments encountered during this procedure,
catheter ablation may be considered in patients who have
experienced VT with a secondary prevention device prior
to implantation of a Tendyne device. It may also be advanta-
geous, in this group of patients, to perform epicardial ablation
at the same sitting as the implant procedure when epicardial
access has been surgically obtained. This is of relevance in
those with nonischemic etiologies when future percutaneous
epicardial access attempts may be hindered by the formation
of adhesions.3References
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